Supernus Announces Year-End and Fourth Quarter 2012 Earnings Conference Call and Webcast

Thu Mar 7, 2013 9:09pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130308:nGNXUXIDCa

ROCKVILLE, Md., March 7, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN),
today announced that the Company expects to report the quarter and year ending December 31, 2012
financial results after the market closes on Thursday, March 14, 2013. Supernus will host a
conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the financial
results, as well as provide an update on other business matters of the Company.

A live webcast will be available at www.supernus.com
http://www.globenewswire.com/newsroom/ctr?d=10024511&l=2&a=www.supernus.com&u=http%3A%2F%2Fwww.supernus.com%2F
. The webcast will be archived on the Company's website for 30 business days following the live
call.

Callers should dial in approximately 10 minutes prior to the start of the call. The phone number
to join the conference call is +1 (877) 288-1043 (U.S. and Canada) or +1 (970) 315-0267
(international and local). The access code for the live call is 99051365.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and
commercializing products for the treatment of central nervous system, or CNS, diseases. The
Company has one marketed product for epilepsy, Oxtellar XR (extended-release oxcarbazepine), and
one tentatively approved product for epilepsy, Trokendi XR (extended-release topiramate). The
Company is also developing several product candidates in psychiatry to address large market
opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

CONTACT: Jack Khattar, President & CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.